Increasing Drug Resistance in Extensively Drug-Resistant Tuberculosis, South Africa

Emerging Infectious Diseases

Volumn 17, Issue 3, 2011, Pages 510-513

  Sarita Shah, N ^a,b,c   Richardson, Jessica ^a,b,c   Moodley, Prashini ^d   Moodley, Salona ^d   Babaria, Palav ^e   Ramtahal, Melissa ^d   Heysell, Scott K ^a   Li, Xuan ^a,b,c   Moll, Anthony P ^f   Friedland, Gerald ^e   Sturm, A Willem ^d   Gandhi, Neel R ^a,b,c  

^a Tugela Ferry Care and Research Collaboration   (South Africa)

^b ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^c MONTEFIORE MEDICAL CENTER   (United States)

^d UNIVERSITY OF KWAZULU NATAL   (South Africa)

^e YALE UNIVERSITY   (United States)

^f Philanjalo Care Center   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

CAPREOMYCIN; ETHAMBUTOL; ETHIONAMIDE; ISONIAZID; KANAMYCIN; OFLOXACIN; RIFAMPICIN; STREPTOMYCIN;

ADULT; ARTICLE; BACTERIAL GROWTH; BACTERIUM CULTURE; BACTERIUM DETECTION; BACTERIUM ISOLATE; CD4 LYMPHOCYTE COUNT; CLINICAL ASSESSMENT; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DRUG RESISTANT TUBERCULOSIS; DRUG SENSITIVITY; FEMALE; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MULTIDRUG RESISTANCE; MYCOBACTERIUM TUBERCULOSIS; PROSPECTIVE STUDY; SOUTH AFRICA; TUBERCULOSIS;

ADULT; ANTITUBERCULAR AGENTS; DRUG RESISTANCE, MULTIPLE, BACTERIAL; EXTENSIVELY DRUG-RESISTANT TUBERCULOSIS; FEMALE; HUMANS; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; MYCOBACTERIUM TUBERCULOSIS; SOUTH AFRICA; TUBERCULOSIS, MULTIDRUG-RESISTANT; YOUNG ADULT;

EID: 79952357466     PISSN: 10806040     EISSN: 10806059     Source Type: Journal    
DOI: 10.3201/eid1703.101363     Document Type: Article

References (12)

1. Shah N, Wright A, Bai G, Barrera L, Boulahbal F, Martan-Casabona N, et al. Worldwide emergence of extensively drug-resistant tuberculosis. Emerg Infect Dis. 2007;13:380-7. DOI: 10.3201/ eid1303.061400
2. World Health Organization. Multidrug and extensively drug-resistant TB (M/XDR-TB): 2010 global report on surveillance and response. Report no. WHO/HTM/TB/2010.3. Geneva: The Organization; 2010
3. Sotgiu G, Ferrara G, Matteelli A, Richardson MD, Centis R, Ruesch- Gerdes S, et al. Epidemiology and clinical management of XDR-TB: a systematic review by TBNET. Eur Respir J. 2009;33:871-81. DOI: 10.1183/09031936.00168008
4. Gandhi NR, Shah NS, Andrews JR, Vella V, Moll AP, Scott M, et al. HIV coinfection in multidrug- and extensively drug-resistant tuberculosis results in high early mortality. Am J Respir Crit Care Med. 2010;181:80-6. DOI: 10.1164/rccm.200907-0989OC
5. Gandhi NR, Moll A, Sturm AW, Pawinski R, Govender T, Lalloo U, et al. Extensively drug-resistant tuberculosis as a cause of death in patients co-infected with tuberculosis and HIV in a rural area of South Africa. Lancet. 2006;368:1575-80. DOI: 10.1016/S0140- 6736(06)69573-1
6. Cox HS, Sibilia K, Feuerriegel S, Kalon S, Polonsky J, Khamraev AK, et al. Emergence of extensive drug resistance during treatment for multidrug-resistant tuberculosis. N Engl J Med. 2008;359:2398-2400. DOI: 10.1056/NEJMc0805644
7. Calver AD, Falmer AA, Murray M, Strauss OJ, Streicher EM, Hanekom M, et al. Emergence of increased resistance and extensively drug-resistant tuberculosis despite treatment adherence, South Africa. Emerg Infect Dis. 2010;16:264-71.
8. Orenstein EW, Basu S, Shah NS, Andrews JR, Friedland GH, Moll AP, et al. Treatment outcomes among patients with multidrugresistant tuberculosis: systematic review and meta-analysis. Lancet Infect Dis. 2009;9:153-61. DOI: 10.1016/S1473-3099(09)70041-6
9. Mitnick CD, Shin SS, Seung KJ, Rich ML, Atwood SS, Furin JJ, et al. Comprehensive treatment of extensively drug-resistant tuberculosis. N Engl J Med. 2008;359:563-74. DOI: 10.1056/NEJMoa0800106
10. Gandhi NR, Nunn P, Dheda K, Schaarf HS, Zignol M, van Soolingen D, et al. Multidrug-resistant and extensively drugresistant tuberculosis: a threat to global control of tuberculosis. Lancet. 2010;375:1830-43. DOI: 10.1016/S0140-6736(10)60410-2
11. Laserson KF, Thorpe LE, Leimane V, Weyer K, Mitnick CD, Riekstina V, et al. Speaking the same language: treatment outcome defi nitions for multidrug-resistant tuberculosis. Int J Tuberc Lung Dis. 2005;9:640-5.
12. Kam KM, Sloutsky A, Yip CW, Bulled N, Seung KJ, Zignol M, et al. Determination of critical concentrations of second-line antituberculosis drugs with clinical and microbiological relevance. Int J Tuberc Lung Dis. 2010;14:282-8.